BridgeBio Pharma Return on Tangible Equity 2018-2024 | BBIO
Current and historical return on tangible equity values for BridgeBio Pharma (BBIO) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| BridgeBio Pharma Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-09-30 |
$-0.44B |
$-1.24B |
36.63% |
| 2024-06-30 |
$-0.45B |
$-1.11B |
38.06% |
| 2024-03-31 |
$-0.54B |
$-1.06B |
42.77% |
| 2023-12-31 |
$-0.64B |
$-1.37B |
49.37% |
| 2023-09-30 |
$-0.61B |
$-1.22B |
47.96% |
| 2023-06-30 |
$-0.57B |
$-1.38B |
45.40% |
| 2023-03-31 |
$-0.43B |
$-1.24B |
36.06% |
| 2022-12-31 |
$-0.48B |
$-1.27B |
42.35% |
| 2022-09-30 |
$-0.49B |
$-1.16B |
46.86% |
| 2022-06-30 |
$-0.51B |
$-1.04B |
53.42% |
| 2022-03-31 |
$-0.60B |
$-1.07B |
73.80% |
| 2021-12-31 |
$-0.56B |
$-0.91B |
88.40% |
| 2021-09-30 |
$-0.54B |
$-0.79B |
140.33% |
| 2021-06-30 |
$-0.50B |
$-0.46B |
377.86% |
| 2021-03-31 |
$-0.52B |
$-0.39B |
-803.09% |
| 2020-12-31 |
$-0.45B |
$0.11B |
-163.72% |
| 2020-09-30 |
$-0.40B |
$0.22B |
-109.76% |
| 2020-06-30 |
$-0.35B |
$0.33B |
-78.15% |
| 2020-03-31 |
$-0.29B |
$0.45B |
-80.55% |
| 2019-12-31 |
$-0.26B |
$0.47B |
-104.42% |
| 2019-06-30 |
$-0.16B |
|
inf% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$5.392B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
